

# OFFICIAL STATEMENT

Published on March 2nd, 2023

## **Diagomics strengthens its position in the cancer diagnosis market by joining the European ZytoMax group.**

### **Diagomics, is an oncology distributor for both research and in vitro diagnosis**

Founded in 2009 by Gwénola Tanneau and localised in Blagnac (France), this firm is specialised in the sales of oncology reagents for both diagnosis and research organisms. It counts 13 employees and it registers a growth over 30 % since its creation.

### **Diagomics and ZytoMax**

To pursue its growth and reinforce its position, Diagomics joined the German ZytoMax group which is Diagomics' first supplier and therefore its historical partner. We are now part of a market leader team for cancer diagnosis which will support us. This will bring together our knowledge and enhance Diagomics' services offer.



### **ZytoMax group**

ZytoMax is specialized in the development, production and sales of diagnostic reagents and system solutions for immunohistology, in situ hybridization and molecular pathology. It regroups three firms: Zytomed Systems, ZytoVision and 42Life Sciences. This well-known leader will support Diagomics in its growth and reinforce its position.

### **New products**

Thanks to these changes, Diagomics will provide customers with the whole range of ZytoVision ISH probes by August 2nd, 2023. It will be the exclusive distributor in France, Belgium and Luxembourg.

From now on, Diagomics will play a role in new products development, which will bring them closer to the market needs.

## A FEW WORDS FROM THE DIAGOMICS FOUNDER

*“After more than 10 years in the diagnostics market, I decided to turn a major corner by selling Diagomics to ZytoMax group. This strategic decision aims to speed up our successful growth history and expand our presence by your side to become an even better and more attractive partner.*

*Originally, ZytoMax is a merger of three Germany-based in vitro diagnostics companies: Zytomed-Systems, ZytoVision and 42 life sciences. ZytoMax is an international market leader in clinical cancer diagnostics and specializes in the development, production and sales of IVD reagents and system solutions for immunohistology, in situ hybridization and molecular pathology.*

*The cornerstones of this new area are the decade-long and trustful business partnership between Diagomics and Zytomes-Systems, our joint innovation potential as well as common values regarding both scientific expertise and close proximity to you, our customers.*

*I have great confidence in ZytoMax, of which I am now also a shareholder and a member of the group’s management team.*

*From a daily business perspective, this change shall not have any effect on you. Diagomics will continue to operate as is with an unchanged team and myself as Managing Director.*

*A page has been turned, and an important era is coming for Diagomics... Looking back, I am especially proud to see that we have come a long way and that we will go many steps further together with ZytoMax.*

*Thank you for your trust.*

Sincerely

Gwénola Tanneau ”

